Skip to content

Type I Interferonopathies in the Differential Diagnosis of Vasculitis: A Comprehensive Review

The finding

This review positions type I interferonopathies—including SAMHD1-associated disease—as a critical diagnostic consideration in patients presenting with vasculitis, particularly when conventional vasculitis workups are unrevealing. The authors provide a clinical framework for recognizing interferonopathy-driven vascular pathology, emphasizing that intracranial aneurysms and cerebrovascular disease can be the presenting feature of underlying innate immune dysregulation rather than classic autoimmune vasculitis.

Where it fits

This paper speaks directly to the clinical outcome layer of the SAMHD1 A565T model—specifically the vascular complications that emerge from chronic type I interferon tone. In the 3D causal model, this maps to the downstream consequences of Loop A (cGAS → STING → IRF3 → IFN-I → JAK-STAT signaling), where tonic interferon production drives ISG expression and vascular remodeling.

The review's emphasis on interferon score monitoring as a diagnostic tool is particularly relevant for the A565T model. Because the heterozygous variant produces a "non-acute chronic inflammation" (NACI) phenotype rather than fulminant Aicardi-Goutières syndrome, interferon scores may be moderately elevated—enough to flag the diagnosis but not enough to trigger the classic interferonopathy workup. The paper's message that vasculitis can be the presenting feature of these conditions supports the model's claim that SAMHD1 disease is multi-system, with vascular outcomes emerging from chronic, low-amplitude innate immune activation.

For clinicians managing A565T patients, this review reinforces that intracranial aneurysm screening should be part of routine surveillance, and that JAK inhibitor responsiveness (a key feature of Loop A) may offer a therapeutic window for vascular protection.

Caveats

  • This is a review article, not a primary study—it synthesizes existing case reports and series rather than presenting new mechanistic data.
  • The review covers type I interferonopathies broadly; findings may not be specific to SAMHD1 p.A565T, which has a distinct heterozygous, partial-loss-of-function profile.
  • No data on whether interferon score thresholds distinguish A565T vasculopathy from other interferonopathies or from classic vasculitis.

What to watch

Whether longitudinal interferon score monitoring can predict aneurysm formation or progression in A565T carriers—and whether early JAK inhibitor intervention alters vascular outcomes.

Source: Type I Interferonopathies in the Differential Diagnosis of Vasculitis: A Comprehensive Review — Journal of Visualized Experiments 2026.